The Liquid Biopsy Solid Tumor test uses next generation sequencing (NGS) performed on cell-free DNA (cfDNA) to identify molecular abnormalities in 277 genes implicated in solid tumors.
The Liquid Biopsy Solid Tumor is recommended for monitoring patients after establishing the molecular abnormalities using a baseline tissue sample. It can be used for detecting minimal residual disease (MRD) or the development of specific resistant mutations related to therapy (e.g. EGFR T790M mutation). We will analyze a tissue diagnostic sample, determine what genes are mutated in that baseline sample, then test the cfDNA for the specific mutations detected in the baseline sample. We will perform liquid biopsy testing for an initial diagnosis if tissue is unavailable.
Baseline tissue sample analysis is essential for proper molecular profiling of cancers. Tissue samples allow for the analysis of the RNA in addition to the DNA. RNA provides incredibly important information on expression pattern, overexpression, fusion genes, alternative splicing and mutations. We recommend tissue biopsy samples not only to establish baseline for monitoring, but for thorough evaluation including possible translocations that may involve ALK, ROS1, RET, NTRK, FGFR, etc. RNA testing allows for evaluation of the microenvironment (immune response, PD-L1, PD-L2, PD-1, CD8 cell, etc.). RNA analysis can also determine the MET exon 14 skipping and various alternative splicing and amplification of HER2, MET and EGFR. RNA information would be missing if the initial evaluation is performed by liquid biopsy alone.
Turn Around Time: 5-7 days
How to complete the Genomic Testing Cooperative requisition form.
Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.
Do You Want to Download the Sample Report?
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia
- Sample Type
- Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
- Results Reported
- Clinical Trial Matching